Nachrichten zur Biogen Inc. Aktie

Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch By Investing.com

Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch…

Biogen (BIIB) Q3 2024 Earnings Call Transcript

BIIB earnings call for the period ending September 30, 2024.…

Biogen raises 2024 EPS guidance with strong Q3 results

…

Biogen raises annual profit forecast as new treatments boost earnings By Reuters

Biogen raises annual profit forecast as new treatments boost earnings…

Alphabet, Biogen, Humana rise premarket; AMD, Eli Lilly fall By Investing.com

Alphabet, Biogen, Humana rise premarket; AMD, Eli Lilly fall…

Biogen raises annual earnings guidance, tops Q3 estimates; shares up By Investing.com

Biogen raises annual earnings guidance, tops Q3 estimates; shares up…

Biogen tops estimates, raises profit guidance as Alzheimers drug Leqembi gains traction

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the companys multiple sclerosis…

Leqembi® revenue totaled JPY 10 billion in the third quarter 2024

Stockholm, Sweden, October 30, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Biogen Beats on Q3 Earnings & Sales, Raises 24 EPS View

BIIBs Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.…

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph…

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen are included in this Analyst Blog.…

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen are included in this Analyst Blog.…

Biogen Aktie: Schwierige Markteinführung von Leqembi führt zu Kurszielsenkung

Toronto (www.aktiencheck.de) - Biogen-Aktienanalyse von BMO Capital Markets: Aktuelle Bewertung BMO Capital-Analyst, Evan Seigerman, hat das Kursziel für Biogen Inc. (ISIN: US09062X1037,…

Biogen receives breakthrough therapy designation for felzartamab, shares edge up By Investing.com

Biogen receives breakthrough therapy designation for felzartamab, shares edge up…

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that felzartamab,…

Biogen Aktie: Wachstumsprobleme bei Leqembi - UBS senkt Kursziel

Zürich (www.aktiencheck.de) - Biogen-Aktienanalyse von UBS: Rating und Kursziel UBS-Analyst Ashwani Verma hat das Kursziel für die Aktie von Biogen Inc. (ISIN:…

UBS sees more downside and than upside in Biogen stock By Investing.com

UBS sees more downside and than upside in Biogen stock…

Biogen-Aktie mit Kursverlusten (172,5736 €)

Am US-amerikanischen Aktienmarkt notiert die Aktie von Biogen gegenwärtig ein wenig leichter. Zuletzt zahlten Investoren für das Wertpapier 191,02 US-Dollar.…

Biogen to end Sage deal for neuro candidate

…

Biogen Aktie: Positive Lupus-Daten bringen Überraschung!

London (www.aktiencheck.de) - Biogen-Aktienanalyse von Barclays: Rating und Kursziel Barclays hat das "equal-weight"-Rating für Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP,…

Biogen Aktie: Lupus-Medikament zeigt Erfolg

Ein führendes Pharmaunternehmen hat positive Ergebnisse aus einer Phase-3-Studie für ein neues Lupus-Medikament bekannt gegeben. Das Präparat, das in Kombination…

Biogens Lupus Candidate Meets Key Goals in Phase III Study

The phase III PHOENYCS GO study evaluating BIIB and UCBs drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets…

Biogen stock opened higher on positive lupus readout By Investing.com

Biogen stock opened higher on positive lupus readout…

Biogen Aktie: Wichtige Erkenntnisse aus der Ärztebefragung

Los Angeles (www.aktiencheck.de) - Biogen-Aktienanalyse von Wedbush Securities: Hintergrund: Wedbush Securities-Analystin Laura Chico hat das Kursziel für Biogen Inc. (ISIN: US09062X1037,…

Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)

…

FED & Verfallstag im Fokus. Chancen & Risiken in DAX, Gold & Aktien wie Nvidia, Biogen, Moderna & Co.

…

Neuemission: BIOGENA legt dritte 7,50%-Anleihe auf - Zeichnung ab sofort möglich

Erneute Anleihe-Emission - die Biogena GmbH & Co. KG legt nach den ersten beiden in diesem Jahr emittierten Unternehmensanleihen direkt…

US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data

Despite favorable views on litifilimab, AbbVie’s Rinvoq and BMS’ Sotyktu capture the most prescriber interest for approval, according to Spherix…

Biogens Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

BIIBs pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the…

Biogen Inc.s (BIIB) Morgan Stanleys 22nd Annual Global Healthcare Conference Transcript

…

Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encouraged to Contact Johnson Fistel, LLP for Their Options

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is conducting a thorough investigation into possible…

Biogen, Beckman Coulter und Fujirebio arbeiten gemeinsam an blutbasierten Biomarkern und Tests für Tau-Pathologie bei Alzheimer-Krankheit

CAMBRIDGE, Massachusets. & BREA, Kalifornien & TOKIO--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc. und Fujirebio gaben eine Zusammenarbeit bekannt,…

dpa-AFX ProFeed